Research programme: enzyme precursors - Propanc

Drug Profile

Research programme: enzyme precursors - Propanc

Alternative Names: PRP-DCM

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Propanc Health Group Corporation
  • Developer Propanc Biopharma
  • Class Enzyme precursors
  • Mechanism of Action PAR-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 18 Jul 2017 Propanc Health Group Corporation enters into research collaboration with the Jaén University to discover new compounds based on the mode of action of naturally derived proenzymes, trypsinogen and chymotrypsinogen
  • 28 Mar 2017 Propanc files for patent protection under Patent Cooperation Treaty for enzyme precursors before March 2017
  • 04 Jan 2017 Propanc files for new patent protection for enzyme precursors in Australia, Spain and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top